Foreign media: Peptide injectables are becoming the latest wellness trend on social media, marketed as miracle drugs that eliminate wrinkles, build muscle, burn fat, and repair injuries. U.S. Health Secretary Robert F. Kennedy Jr. has also publicly endorsed them. However, Nature points out that these popular unapproved peptides—such as BPC-157, MOTS-c, and TB-500—are mostly labeled "for research use only," operating entirely outside regulatory oversight.
Scientific evidence shows some potential in animal studies—for instance, MOTS-c has demonstrated anti-obesity effects and lifespan extension in mice, though human trials were halted due to insufficient funding; BPC-157 has only three pilot studies totaling 30 participants, with questionable quality. Even more concerning is the safety issue: third-party testing revealed that over 40% of around 6,000 samples failed basic purity standards, and 15% contained bacterial endotoxins.
In April 2026, the FDA will begin easing restrictions on pharmacy compounding of these compounds, but experts warn this could undermine pharmaceutical companies' motivation to conduct proper clinical trials, leading to widespread public use without sufficient evidence on effectiveness or safety.
Original source: toutiao.com/article/1867688545640512/
Disclaimer: This article represents the personal views of the author